Arrowhead Pharmaceuticals (ARWR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$669.5M

Revenue (quarter)

$75.3M

Revenue growth (year over year)

+171.02%

Gross profit (trailing twelve months)

$669.5M

Gross margin

100.00%

Net income (trailing twelve months)

−$272.1M

Net income (quarter)

−$178.9M

Net income growth (year over year)

−0.15%

Net margin

−40.65%

Return on equity

−64.78%

EPS (trailing twelve months)

−$2.28

Book value per share

$3.30

P/E (trailing twelve months)

—

Price to book

17.49

Debt to assets

77.93%

Payout ratio

—

Dividend yield

—

Company profile

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.

• Is Arrowhead Pharmaceuticals (ARWR) profitable?

  No. Arrowhead Pharmaceuticals reported a net loss of $272.1M over the trailing twelve months.

• How much revenue does Arrowhead Pharmaceuticals (ARWR) make?

  Arrowhead Pharmaceuticals generated $669.5M in revenue over the trailing twelve months, up 171.02% year over year.

• How do I buy stock in Arrowhead Pharmaceuticals (ARWR)?

  ARWR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.